This article first appeared on GuruFocus .
Release Date: January 21, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Rallis India Ltd ( BOM:500355 ) reported a 19% increase in Q3 FY26 revenue, reaching INR 623 crore compared to INR 522 crore in the same period last year.
-
The company's export business showed significant growth, with a 73% increase in top-line revenue, driven by volume growth and expansion in the customer base.
-
The seeds business experienced a 46% revenue growth in Q3 FY26, supported by strong performance in paddy, mustard, and wheat.
-
Rallis India Ltd launched nine new products in the first nine months of FY26, including seven herbicides and two fungicides, enhancing its product portfolio.
-
The company has been granted Indian and US patents for new formulations, indicating a strong focus on innovation and intellectual property.
Negative Points
-
Profit after tax for Q3 FY26 was INR 2 crore, which is 81% lower than the previous year's INR 11 crore, primarily due to exceptional items including gratuity provisions.
-
The domestic crop protection segment faced challenges, with pricing de-growth of 8% despite an 18% revenue growth.
-
The agrochemical market remains competitive, with limited pricing power due to global competition, particularly from China.
-
Rallis India Ltd's inventory levels remain slightly elevated compared to the same quarter last year, indicating potential inefficiencies in inventory management.
-
The company faces ongoing regulatory challenges in the bio-fertilizer segment, although it has made progress in compliance and production migration.
Q & A Highlights
-
Warning! GuruFocus has detected 4 Warning Signs with BOM:500355.
-
Is BOM:500355 fairly valued? Test your thesis with our free DCF calculator.
Q: Can you provide the volume and price trends for the quarter in the domestic B2C and international business, and any insights on inventory liquidation? A: Dr. Ganindra Shukla, Managing Director and CEO, explained that there was significant growth in the seed business and export business, with a 73% increase in exports and a 46% increase in seeds. The domestic crop protection segment grew by 18%. Bhaskar Swainathan, CFO, added that the quarter saw a 12% positive impact from volume and a 32% negative impact from price in the domestic B2C segment. The company is managing inventory carefully to align with market demand.
Q: How will the discontinuation of the Chinese VAT rebate impact your technical exports? A: Dr. Ganindra Shukla noted that the rebate removal is applicable from April and could lead to price increases and consolidation in China. The company does not export Etheon but focuses on products like Metrobizine and hexaconazole. The impact will depend on how much supply has already been provided by Chinese companies.
Q: What is your strategy for deploying the growing cash balance on the balance sheet? A: Dr. Ganindra Shukla stated that the cash will be used to meet working capital requirements and potentially negotiate better prices. The company is also looking for inorganic growth opportunities in its verticals to utilize the cash effectively.
Q: Can you provide insights into the regulatory status of bio-fertilizers and the challenges faced? A: Dr. Ganindra Shukla mentioned that regulatory changes are generally beneficial for large organized players. The company has addressed most regulatory issues and has moved production in-house for certain biostimulants, resulting in a 16% growth in the soil and plant health category.
Q: What is your outlook for the international business given the current geopolitical and market conditions? A: Dr. Ganindra Shukla indicated that while the company has recovered from past setbacks, the international business environment remains uncertain due to geopolitical factors and crop price softening. The focus remains on seeking registrations, partnerships, and adding new customers to navigate these challenges.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
